Research programme: reproductive health therapeutics - Pantarhei Biosciences

Drug Profile

Research programme: reproductive health therapeutics - Pantarhei Biosciences

Alternative Names: BLACE; OTE F; Oxytocin/estrogen - Pantarhei Biosciences; Renin angiotensin system suppressors - Pantarhei Biosciences; Testetrol - Pantarhei Biosciences

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pantarhei Bioscience
  • Class Hormonal replacements; Hormones
  • Mechanism of Action ACE inhibitors; Angiogenesis inhibitors; Angiotensin receptor antagonists; Estrogen receptor agonists; Oxytocin receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Female testosterone deficiency; Hypogonadism
  • Research Menopausal syndrome
  • No development reported Male infertility

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Male-infertility in Netherlands
  • 21 Oct 2015 Pantarhei Biosciences has patents pending for testetrol and BLACE
  • 21 Oct 2015 Early research in Menopausal syndrome in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top